These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 18959605

  • 1. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 2. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 3. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 4. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 5. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G, Strange P.
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [Abstract] [Full Text] [Related]

  • 6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 7. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M, Marchionni N, Mannucci E.
    Diabetes Res Clin Pract; 2008 Aug 09; 81(2):184-9. PubMed ID: 18495286
    [Abstract] [Full Text] [Related]

  • 8. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
    Home PD, Fritsche A, Schinzel S, Massi-Benedetti M.
    Diabetes Obes Metab; 2010 Sep 09; 12(9):772-9. PubMed ID: 20649629
    [Abstract] [Full Text] [Related]

  • 9. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan 09; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 10. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov 09; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 11. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.
    Diabetes Res Clin Pract; 2010 Jan 09; 87(1):108-16. PubMed ID: 19896233
    [Abstract] [Full Text] [Related]

  • 12. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct 09; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 13. Insulin glargine for type 2 diabetes.
    Hemraj F, Garces K.
    Issues Emerg Health Technol; 2004 Aug 09; (59):1-4. PubMed ID: 15311441
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M.
    Diabetes Res Clin Pract; 2006 Jul 09; 73(1):35-40. PubMed ID: 16513202
    [Abstract] [Full Text] [Related]

  • 15. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H.
    Eur J Clin Invest; 2004 Jun 09; 34(6):410-6. PubMed ID: 15200492
    [Abstract] [Full Text] [Related]

  • 16. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C, Jung R, Hofmann U.
    Horm Metab Res; 2008 Aug 09; 40(8):544-8. PubMed ID: 18493882
    [Abstract] [Full Text] [Related]

  • 17. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.
    Exp Clin Endocrinol Diabetes; 2008 May 09; 116(5):282-8. PubMed ID: 18484560
    [Abstract] [Full Text] [Related]

  • 18. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M, Tapanainen P, Veijola R.
    Pediatr Diabetes; 2008 Jun 09; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [Abstract] [Full Text] [Related]

  • 19. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F, Carabino JM, Vergara CM.
    Clin Ther; 2003 Jun 09; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [Abstract] [Full Text] [Related]

  • 20. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar 09; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.